CN111148513A - 一种包含地佐辛类似物酯的缓释混悬液及其制备方法 - Google Patents

一种包含地佐辛类似物酯的缓释混悬液及其制备方法 Download PDF

Info

Publication number
CN111148513A
CN111148513A CN201880025194.7A CN201880025194A CN111148513A CN 111148513 A CN111148513 A CN 111148513A CN 201880025194 A CN201880025194 A CN 201880025194A CN 111148513 A CN111148513 A CN 111148513A
Authority
CN
China
Prior art keywords
oil
suspension
sustained release
release suspension
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880025194.7A
Other languages
English (en)
Other versions
CN111148513B (zh
Inventor
张杨
邓冰
吴家虎
伍文韬
李志祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Danhong Pharmaceutical Co Ltd
Original Assignee
Shandong Danhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Danhong Pharmaceutical Co Ltd filed Critical Shandong Danhong Pharmaceutical Co Ltd
Publication of CN111148513A publication Critical patent/CN111148513A/zh
Application granted granted Critical
Publication of CN111148513B publication Critical patent/CN111148513B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了一种包含地佐辛类似物酯的缓释混悬液及其制备方法。本发明选择药学上作为缓释储库的可注射的油性辅料和赋形剂，采用微粉化技术并联合高压均质技术、反溶剂法成功制备了供注射用的长效混悬液。它主要成分为式(Ⅰ)所示化合物、可注射用油等。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201880025194.7A 2017-07-04 2018-09-03 一种包含地佐辛类似物酯的缓释混悬液及其制备方法 Active CN111148513B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710539419 2017-07-04
PCT/CN2018/103854 WO2019007443A1 (zh) 2017-07-04 2018-09-03 一种包含地佐辛类似物酯的缓释混悬液及其制备方法

Publications (2)

Publication Number Publication Date
CN111148513A true CN111148513A (zh) 2020-05-12
CN111148513B CN111148513B (zh) 2023-03-17

Family

ID=64949753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880025194.7A Active CN111148513B (zh) 2017-07-04 2018-09-03 一种包含地佐辛类似物酯的缓释混悬液及其制备方法

Country Status (5)

Country Link
US (1) US10744109B2 (zh)
EP (1) EP3603629B1 (zh)
JP (1) JP6850371B2 (zh)
CN (1) CN111148513B (zh)
WO (2) WO2019007441A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112315901A (zh) * 2019-07-17 2021-02-05 成都康弘药业集团股份有限公司 一种注射用浓溶液及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3608306B1 (en) * 2017-07-03 2022-05-25 Shandong Danhong Pharmaceutical Co., Ltd. Crystal form and amorphous form of dezocine analogue hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142458A (zh) * 2013-01-22 2013-06-12 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
WO2017118375A1 (zh) * 2016-01-04 2017-07-13 南京明德新药研发股份有限公司 地佐辛类似物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201019525D0 (en) 2010-11-18 2010-12-29 Shire Llc Oil-based formulations
CN104274473A (zh) 2013-07-11 2015-01-14 青岛康地恩药业股份有限公司 含盐酸多西环素、氟尼辛葡甲胺的油混悬液及其制备方法
CN104523584B (zh) 2014-12-22 2018-03-30 扬子江药业集团有限公司 一种地佐辛的注射剂及其制备方法
CN104622803A (zh) 2015-03-09 2015-05-20 邳州正康生物技术有限公司 一种治疗泌乳期奶牛乳房炎的乳房注入剂及制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142458A (zh) * 2013-01-22 2013-06-12 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
WO2017118375A1 (zh) * 2016-01-04 2017-07-13 南京明德新药研发股份有限公司 地佐辛类似物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112315901A (zh) * 2019-07-17 2021-02-05 成都康弘药业集团股份有限公司 一种注射用浓溶液及其制备方法

Also Published As

Publication number Publication date
US10744109B2 (en) 2020-08-18
EP3603629B1 (en) 2022-10-12
WO2019007443A1 (zh) 2019-01-10
WO2019007441A1 (zh) 2019-01-10
US20200188342A1 (en) 2020-06-18
JP6850371B2 (ja) 2021-03-31
EP3603629A1 (en) 2020-02-05
JP2020527543A (ja) 2020-09-10
CN111148513B (zh) 2023-03-17
EP3603629A4 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
Indulkar et al. Origin of nanodroplet formation upon dissolution of an amorphous solid dispersion: a mechanistic isotope scrambling study
US20100267818A1 (en) Stabilized single-liquid pharmaceutical composition containing docetaxel
KR20120030561A (ko) 아세나핀을 함유하는 주사가능한 제제 및 그를 사용한 치료 방법
CN111148513B (zh) 一种包含地佐辛类似物酯的缓释混悬液及其制备方法
CN102170861A (zh) 包含噻托铵的可吸入颗粒
Xie et al. Controlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studies
Lei et al. Enhanced oral bioavailability of glycyrrhetinic acid via nanocrystal formulation
CN104523606B (zh) 自组装法制备棉酚及其衍生物普朗尼克纳米粒子的方法
Singh et al. Nanoemulsion system for improvement of raspberry ketone oral bioavailability
CN111991355A (zh) 含纳米级大麻二酚的固体纳米粉组合物、制备方法及用途
CN114748428B (zh) 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法
CN108553417B (zh) 一种蛇床子素自乳化释药系统及其制备方法与用途
CN114224834B (zh) 一种具有较高生物利用度的阿苯达唑纳米混悬剂及其制备方法
Patel et al. Formulation and evaluation of raloxifene hydrochloride dry emulsion tablet using solid carrier adsorption technique
EP3270891A1 (en) Nanoparticles comprising a stabilized boronic acid compound
CN104490764A (zh) 一种喜树碱纳米凝胶
Mao et al. Cefquinome sulfate oily nanosuspension designed for improving its bioavailability in the treatment of veterinary infections
CN108853074A (zh) 一种含有溴芬酸钠水合物的药物水性滴眼液及其制备方法
CN103340830B (zh) 注射用更昔洛韦纳米囊冻干制剂及其制备方法
CN101081213B (zh) 丁二酸(5-雄甾烯-17-酮-3β-羟基)二酯固体分散体及其制备方法与应用
CN105125490A (zh) 一种氟苯尼考纳米乳及其制备方法
Han et al. Enabling a novel solvent method on Albendazole solid dispersion to improve the in vivo bioavailability
CN110812335A (zh) 装载疏水药物的丝素蛋白微纳米颗粒缓释制剂及制备方法
CN102772365A (zh) 4-(4-(3-三氟甲基)苯甲酰胺基苯氧基)-2-(甲基氨甲酰基)吡啶纳米混悬剂及其制法和应用
Sun et al. Preparation and pharmacokinetics study of albumin-coated crystalline progesterone long-acting microcapsules for injection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant